with return to OR for bleeding, primary graft dysfunction, longer length of stay and increased resource utilization was reported [6]. Thus, it would be helpful, if more details on post-transplant complications between groups could be provided. The survival data, which are limited to an unadjusted Kaplan-Meier survival analysis comparing conventional with lobar LTx, make it difficult to interpret the results in context. The lobar LTx group consisted predominantly of patients with cystic fibrosis, who in general have the most favourable long-term survival. It would be informative if the authors could show analysis within the same diagnostic groups (i.e. cystic fibrosis). Furthermore, providing a multivariate Cox proportional hazard model adjusted for important confounders would strengthen the assessment of clinical outcomes.

We wish to conclude by thanking and congratulating Inci et al. on their important study on bilateral lobar LTx allowing life-saving transplants in ‘short’ recipients, who otherwise might not be able to receive an appropriately sized allograft in a timely way.

**REFERENCES**


**LETTER TO THE EDITOR RESPONSE**

Reply to Eberlein et al.

Ilhan Inci* and Walter Weder

Department of Thoracic Surgery, University Hospital, Zurich, Switzerland

* Corresponding author. Department of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland. Tel: +41-44-2558802; fax: +41-44-2558805; e-mail: ilhan.inci@usz.ch (I. Inci).

Received 21 December 2012; accepted 3 January 2013

**Keywords:** Lung transplantation • Lobar transplantation • Size-reduced lung transplantation

We thank Eberlein et al. [1] for their interest in our article [2]. The purpose of our study [2] was not to show that oversized grafts are associated with more perioperative complications and worse outcome compared with standard lung transplantation. In our experience, oversized lung grafts can potentially lead to atelectasis and impaired airway clearance, which leads to a more complicated postoperative course [3]. Optimal size matching is therefore very important. For optimal size matching, different methods have been proposed, such as donor-recipient difference or ratio of body weight and height [4, 5]. In addition, chest circumference and chest x-ray vertical and transverse dimensions have been used [4]. Others have used donor and recipient total lung capacity (TLC) [4, 5]. Interestingly, a recent US study showed that overall post-transplant survival or lung function after standard lung transplantation was unaffected by donor-to-recipient predicted TLC ratio and actual TLC ratio [6]. We also calculated donor-predicted TLC/recipient-predicted TLC ratio (pTLC ratio) (Data not given in original article [2]). Median pTLC ratio was 1.5 (range, 0.84–2.44). In only one recipient this ratio was 0.84 and in all other 22 recipients, more than 1. In addition, there is a very significant correlation between pTLC ratio and donor-recipient height difference (r = 0.903, P = 0.01, Pearson correlation test) and also between pTLC ratio and percentage of donor-recipient height discrepancy (r = 0.924, P = 0.01, Pearson correlation test). According to these data, it is also possible and reliable to decide size mismatch with donor-recipient height difference. We reported a rate of 39% haemothorax requiring reoperation [2]. Nineteen (83%) of the transplantations were performed with extracorporeal membrane oxygenation (ECMO) support. Three recipients were on ECMO perioperative course [7]. Delayed chest closure assessed by transesophageal echocardiogram in single-lobe lung transplantation. Ann Thorac Surg 2011;92:2254–7.

**REFERENCES**


Red cell distribution width is a predictor of mortality in patients undergoing coronary artery bypass surgery

Sevket Baltaa,*, Sait Demirkola, Mehmet Aydoganb and Murat Unluc

a Department of Cardiology, Gulhane Medical Academy, Ankara, Turkey
b Department of Pulmonary Medicine, Gulhane Medical Academy, Ankara, Turkey

* Corresponding author. Department of Cardiology, Gulhane School of Medicine, Tevfik Ságlam St., 06018 Etilk-Ankara, Turkey. Tel: +90-312-3044281; fax: +90-312-3044250; e-mail: dsevketb@gmail.com (S. Balta).

Received 16 January 2013; accepted 22 January 2013

Keywords: Red cell distribution width • Coronary artery bypass surgery • Inflammation

We read with interest the article ‘Red cell distribution width and coronary artery bypass surgery’ by Warwick et al., [1]. They aimed to investigate the effect of red cell distribution width (RDW)—after adjustment for the haemoglobin level—on in-hospital mortality, long-term survival, myocardial damage as assessed by creatine kinase muscle–brain (CKMB) isoenzyme release and the length of hospital and intensive care unit (ICU). They concluded that the RDW was a significant factor determining in-hospital mortality and long-term survival, but that it had no significant effect on CKMB release or length of stay in ICU or hospital. Confounding factor analysis revealed that, in the absence of anaemia, the RDW was still a significant factor determining in-hospital mortality and long-term survival. They suggested that the RDW may be a significant factor determining in-hospital mortality and long-term survival in patients undergoing isolated coronary artery bypass graft (CABG). We believe that these findings will enlighten further studies on the relationships between RDW and coronary artery bypass surgery. Thanks to the authors for their contribution.

RDW has recently been identified as an independent predictor of all-cause mortality, combined cardiovascular mortality and morbidity. GFR may be useful in identifying those patients undergoing CABG with subclinical chronic kidney disease [3]. For this reason, it would be better if the authors mentioned any of these possible conditions.

Present studies have shown that elevated levels of inflammatory markers are markers of atherosclerotic disease activity. These molecules also indicate an increased risk of the progression of CABG and they can be reduced by medications such as antihypertensive therapy and acetylsalicylic acid treatment [4, 5]. Additionally, not only RDW but also neutrophil lymphocyte ratio, gamma-glutamyltransferase, C-reactive protein, mean platelet volume and uric acid are markers easily used to assess the cardiovascular disease of the patients [6]. These markers might be useful in clinical practice. RDW itself, alone without other inflammatory markers, may not give information to clinicians about the inflammatory condition and prognostic indication of the patients. So we think that it should be evaluated together with other serum inflammatory markers. Finally, it would be better if the authors defined their timescale for measuring RDW levels, because delay in blood sampling can cause abnormal results in RDW measurements.

REFERENCES